Functional cargo delivery into mouse and human fibroblasts using a versatile microfluidic device

Kevin H. Lam, Antonio Fernandez-Perez, David W. Schmidtke, Nikhil V. Munshi

Research output: Contribution to journalArticle

Abstract

Efficient intracellular cargo delivery is a key hurdle for the translation of many emerging stem cell and cellular reprogramming therapies. Recently, a microfluidic-based device constructed from silicon was shown to transduce macromolecules into cells via shear-induced formation of plasma membrane pores. However, the scalability and widespread application of the current platform is limited since physical deformation-mediated delivery must be optimized for each therapeutic application. Therefore, we sought to create a low-cost, versatile device that could facilitate rapid prototyping and application-specific optimization in most academic research labs. Here we describe the design and implementation of a microfluidic device constructed from Polydimethylsiloxane (PDMS) that we call Cyto-PDMS (Cytoplasmic PDMS-based Delivery and Modification System). Using a systematic Cyto-PDMS workflow, we demonstrate intracellular cargo delivery with minimal effects on cellular viability. We identify specific flow rates at which a wide range of cargo sizes (1–70 kDa) can be delivered to the cell interior. As a proof-of-principle for the biological utility of Cyto-PDMS, we show (i) F-actin labeling in live human fibroblasts and (ii) intracellular delivery of recombinant Cre protein with appropriate genomic recombination in recipient fibroblasts. Taken together, our results demonstrate that Cyto-PDMS can deliver small-molecules to the cytoplasm and biologically active cargo to the nucleus without major effects on viability. We anticipate that the cost and versatility of PDMS can be leveraged to optimize delivery to a broad array of possible cell types and thus expand the potential impact of cellular therapies.

Original languageEnglish (US)
Article number52
JournalBiomedical Microdevices
Volume20
Issue number3
DOIs
StatePublished - Sep 1 2018

Fingerprint

Lab-On-A-Chip Devices
Polydimethylsiloxane
Fibroblasts
Microfluidics
Costs and Cost Analysis
Recombinant proteins
Workflow
Rapid prototyping
Silicon
Cell membranes
Stem cells
Macromolecules
Recombinant Proteins
Labeling
Genetic Recombination
Scalability
Actins
Costs
Cytoplasm
Stem Cells

Keywords

  • Actin network
  • Drug delivery
  • Intracellular cargo delivery
  • PDMS

ASJC Scopus subject areas

  • Biomedical Engineering
  • Molecular Biology

Cite this

Functional cargo delivery into mouse and human fibroblasts using a versatile microfluidic device. / Lam, Kevin H.; Fernandez-Perez, Antonio; Schmidtke, David W.; Munshi, Nikhil V.

In: Biomedical Microdevices, Vol. 20, No. 3, 52, 01.09.2018.

Research output: Contribution to journalArticle

Lam, Kevin H. ; Fernandez-Perez, Antonio ; Schmidtke, David W. ; Munshi, Nikhil V. / Functional cargo delivery into mouse and human fibroblasts using a versatile microfluidic device. In: Biomedical Microdevices. 2018 ; Vol. 20, No. 3.
@article{77337d752fb541918b54f8e8ff706ad5,
title = "Functional cargo delivery into mouse and human fibroblasts using a versatile microfluidic device",
abstract = "Efficient intracellular cargo delivery is a key hurdle for the translation of many emerging stem cell and cellular reprogramming therapies. Recently, a microfluidic-based device constructed from silicon was shown to transduce macromolecules into cells via shear-induced formation of plasma membrane pores. However, the scalability and widespread application of the current platform is limited since physical deformation-mediated delivery must be optimized for each therapeutic application. Therefore, we sought to create a low-cost, versatile device that could facilitate rapid prototyping and application-specific optimization in most academic research labs. Here we describe the design and implementation of a microfluidic device constructed from Polydimethylsiloxane (PDMS) that we call Cyto-PDMS (Cytoplasmic PDMS-based Delivery and Modification System). Using a systematic Cyto-PDMS workflow, we demonstrate intracellular cargo delivery with minimal effects on cellular viability. We identify specific flow rates at which a wide range of cargo sizes (1–70 kDa) can be delivered to the cell interior. As a proof-of-principle for the biological utility of Cyto-PDMS, we show (i) F-actin labeling in live human fibroblasts and (ii) intracellular delivery of recombinant Cre protein with appropriate genomic recombination in recipient fibroblasts. Taken together, our results demonstrate that Cyto-PDMS can deliver small-molecules to the cytoplasm and biologically active cargo to the nucleus without major effects on viability. We anticipate that the cost and versatility of PDMS can be leveraged to optimize delivery to a broad array of possible cell types and thus expand the potential impact of cellular therapies.",
keywords = "Actin network, Drug delivery, Intracellular cargo delivery, PDMS",
author = "Lam, {Kevin H.} and Antonio Fernandez-Perez and Schmidtke, {David W.} and Munshi, {Nikhil V.}",
year = "2018",
month = "9",
day = "1",
doi = "10.1007/s10544-018-0292-6",
language = "English (US)",
volume = "20",
journal = "Biomedical Microdevices",
issn = "1387-2176",
publisher = "Kluwer Academic Publishers",
number = "3",

}

TY - JOUR

T1 - Functional cargo delivery into mouse and human fibroblasts using a versatile microfluidic device

AU - Lam, Kevin H.

AU - Fernandez-Perez, Antonio

AU - Schmidtke, David W.

AU - Munshi, Nikhil V.

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Efficient intracellular cargo delivery is a key hurdle for the translation of many emerging stem cell and cellular reprogramming therapies. Recently, a microfluidic-based device constructed from silicon was shown to transduce macromolecules into cells via shear-induced formation of plasma membrane pores. However, the scalability and widespread application of the current platform is limited since physical deformation-mediated delivery must be optimized for each therapeutic application. Therefore, we sought to create a low-cost, versatile device that could facilitate rapid prototyping and application-specific optimization in most academic research labs. Here we describe the design and implementation of a microfluidic device constructed from Polydimethylsiloxane (PDMS) that we call Cyto-PDMS (Cytoplasmic PDMS-based Delivery and Modification System). Using a systematic Cyto-PDMS workflow, we demonstrate intracellular cargo delivery with minimal effects on cellular viability. We identify specific flow rates at which a wide range of cargo sizes (1–70 kDa) can be delivered to the cell interior. As a proof-of-principle for the biological utility of Cyto-PDMS, we show (i) F-actin labeling in live human fibroblasts and (ii) intracellular delivery of recombinant Cre protein with appropriate genomic recombination in recipient fibroblasts. Taken together, our results demonstrate that Cyto-PDMS can deliver small-molecules to the cytoplasm and biologically active cargo to the nucleus without major effects on viability. We anticipate that the cost and versatility of PDMS can be leveraged to optimize delivery to a broad array of possible cell types and thus expand the potential impact of cellular therapies.

AB - Efficient intracellular cargo delivery is a key hurdle for the translation of many emerging stem cell and cellular reprogramming therapies. Recently, a microfluidic-based device constructed from silicon was shown to transduce macromolecules into cells via shear-induced formation of plasma membrane pores. However, the scalability and widespread application of the current platform is limited since physical deformation-mediated delivery must be optimized for each therapeutic application. Therefore, we sought to create a low-cost, versatile device that could facilitate rapid prototyping and application-specific optimization in most academic research labs. Here we describe the design and implementation of a microfluidic device constructed from Polydimethylsiloxane (PDMS) that we call Cyto-PDMS (Cytoplasmic PDMS-based Delivery and Modification System). Using a systematic Cyto-PDMS workflow, we demonstrate intracellular cargo delivery with minimal effects on cellular viability. We identify specific flow rates at which a wide range of cargo sizes (1–70 kDa) can be delivered to the cell interior. As a proof-of-principle for the biological utility of Cyto-PDMS, we show (i) F-actin labeling in live human fibroblasts and (ii) intracellular delivery of recombinant Cre protein with appropriate genomic recombination in recipient fibroblasts. Taken together, our results demonstrate that Cyto-PDMS can deliver small-molecules to the cytoplasm and biologically active cargo to the nucleus without major effects on viability. We anticipate that the cost and versatility of PDMS can be leveraged to optimize delivery to a broad array of possible cell types and thus expand the potential impact of cellular therapies.

KW - Actin network

KW - Drug delivery

KW - Intracellular cargo delivery

KW - PDMS

UR - http://www.scopus.com/inward/record.url?scp=85049344425&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049344425&partnerID=8YFLogxK

U2 - 10.1007/s10544-018-0292-6

DO - 10.1007/s10544-018-0292-6

M3 - Article

C2 - 29938310

AN - SCOPUS:85049344425

VL - 20

JO - Biomedical Microdevices

JF - Biomedical Microdevices

SN - 1387-2176

IS - 3

M1 - 52

ER -